AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025

AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. ^[1]

Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. ^[2]

Today’s news flow (November 29, 2025) gives investors plenty to chew on:

A major reimbursement win in Canada for Skyrizi in ulcerative colitis, now being reframed by analysts as a potential catalyst for the stock’s long‑term narrative. ^[3]
A flurry of institutional 13F filings showing big asset managers tweaking their AbbVie exposure. ^[4]
Fresh valuation pieces from Simply Wall St and Yahoo Finance questioning whether ABBV remains undervalued after the rally. ^[5]

Below is a detailed, SEO‑friendly breakdown of what’s moving AbbVie stock right now and how today’s headlines fit into the bigger story.

AbbVie Stock Price Today and Recent Performance

Last close (Nov 28, 2025): $227.70
After‑hours (Nov 28): around $227.80 ^[6]
1‑day move: +0.02%
52‑week range: approximately $164.39 – $244.81 ^[7]

Historical data from multiple sources confirm that ABBV finished Friday’s session near the upper end of its yearly range, after a multi‑month climb powered by robust demand for Skyrizi and Rinvoq. ^[8]

According to recent analysis, AbbVie shares are up 31.7% in 2025 and about 38.2% over the last year, underscoring how strongly the market has rewarded its post‑Humira transition so far. ^[9]

From a fundamentals snapshot:

Market cap: ~$402 billion ^[10]
Dividend yield (forward): around 3.0–3.1% based on a new annualized payout of $6.92 per share. ^[11]

Today’s Big Story: Skyrizi’s Canada Reimbursement Win and the AbbVie Investment Narrative

The most strategically important “current news” around AbbVie this week — and explicitly highlighted again today — is the Canadian reimbursement decision for Skyrizi in ulcerative colitis (UC).

Skyrizi gains public‑plan backing in Canada

On November 28, 2025, AbbVie Canada announced that Canada’s Drug Agency (CDA‑AMC) has issued a positive reimbursement recommendation for Skyrizi (risankizumab) in adults with moderately to severely active ulcerative colitis who have failed or are intolerant to conventional therapy, a biologic, or a JAK inhibitor. ^[12]

Key points from AbbVie’s Canadian press release:

The CDA‑AMC recommendation follows earlier, separate positive guidance for Skyrizi in Crohn’s disease, reinforcing the drug’s positioning as a core inflammatory bowel disease (IBD) therapy. ^[13]
AbbVie has concluded a Letter of Intent (LOI) with the pan‑Canadian Pharmaceutical Alliance (pCPA) on Skyrizi for UC, clearing the way for public drug-plan coverage across provinces. ^[14]
The decision was informed by feedback from Canadian clinicians and patient organizations, including Crohn’s and Colitis Canada, emphasizing unmet need in UC. ^[15]

In practical terms, this doesn’t immediately show up as a huge revenue spike, but it expands reimbursed access in a developed market where IBD prevalence is rising. For investors, it is another data point that AbbVie continues to grow Skyrizi beyond psoriasis and Crohn’s disease and deepen its immunology moat.

Simply Wall St: Skyrizi Canada move “changes the case” (slightly)

A new Simply Wall St article published today (Nov 29, 2025) explicitly frames the Canadian decision as something that “might change the case for investing in AbbVie (ABBV).” ^[16]

Highlights from that piece:

The reimbursement win is described as incrementally strengthening AbbVie’s immunology narrative, adding to earlier regulatory wins like FDA approval of EPKINLY in follicular lymphoma, and helping diversify the portfolio beyond Humira. ^[17]
Their forward narrative projects AbbVie reaching about $73 billion in revenue and $20.8 billion in earnings by 2028, implying ~7.7% annual revenue growth from current levels. ^[18]
Under those assumptions, they calculate a “fair value” of roughly $243.55 per share — only about 7% upside from the current price, suggesting ABBV is close to fairly valued on that particular model. ^[19]

That contrasts sharply with another Simply Wall St valuation piece this week, which used a pure discounted cash‑flow (DCF) model and concluded AbbVie might be trading at a ~45% discount to an intrinsic value near $430 per share. ^[20]

Takeaway:

Today’s narrative‑focused analysis says modest upside (~7%).
The more aggressive DCF model implies substantial undervaluation (~45%).

Both use reasonable assumptions, which is why you’re seeing a “valuation debate” headline around AbbVie today rather than a clear consensus.

November 29 Filings: Institutional Investors Rebalance AbbVie Positions

A notable chunk of today’s AbbVie news feed comes from MarketBeat’s coverage of fresh 13F filings, summarizing how large funds adjusted their ABBV stakes in Q2 2025. These filings are backward‑looking, but the fact they’re all hitting the tape on November 29 makes them part of today’s news cycle.

Big holders trimming exposure

Several major institutions reported modest reductions in their AbbVie holdings:

Mackenzie Financial Corp
- Sold 162,035 ABBV shares, trimming its stake by 6.5%.
- Now holds about 2.34 million shares worth roughly $433.9 million, representing ~0.13% of the company. ^[21]
Schroder Investment Management Group
- Cut its AbbVie stake by 6.4%, selling 176,770 shares.
- Now owns about 2.56 million shares valued around $476 million. ^[22]
New York State Common Retirement Fund
- Sold 22,300 shares, a 1% reduction in Q2.
- Still holds roughly 2.19 million ABBV shares (~0.12% of AbbVie), valued at over $406 million, making ABBV its 24th‑largest holding. ^[23]
Virtue Capital Management LLC
- Reduced its position by 28.9%, selling 1,371 shares.
- Now owns 3,376 shares worth about $627,000. ^[24]

These moves look more like portfolio rebalancing after a strong run rather than an exodus: stakes remain large and ABBV continues to rank as a top‑tier holding for some of these funds.

Smaller players piling in

At the same time, other institutions disclosed new or sharply increased positions, also reported today:

West Family Investments Inc.
- Boosted its AbbVie stake by 40.3%, buying 2,862 shares.
- Now holds 9,960 shares worth about $1.85 million. ^[25]
Berry Wealth Group LP
- Increased its ABBV holdings by 479.2% to 16,804 shares, valued around $3.12 million; AbbVie is now about 2.2% of its portfolio. ^[26]
First National Advisers LLC
- Lifted its stake by a huge 2,086.6%, ending Q2 with 22,413 shares worth approximately $4.16 million. ^[27]
Independent Family Office LLC
- Opened a new position, buying 1,157 ABBV shares valued near $215,000. ^[28]

Across these MarketBeat write‑ups, a common theme is that institutional ownership remains high. Aggregated data (also relayed via Longbridge) suggest institutions and hedge funds control roughly 70.2% of AbbVie’s float, with giants like Vanguard and Norges Bank holding multi‑billion‑dollar positions. ^[29]

For SEO purposes: institutional ownership of AbbVie stock and hedge fund activity in ABBV are likely to remain key search phrases as long as this rebalancing continues.

Analyst Ratings and Today’s Valuation Discussion

Consensus: “Moderate Buy” with mid‑single‑digit upside

Across major data platforms, AbbVie still carries a “Buy” or “Moderate Buy” consensus:

MarketBeat aggregates about 25 analysts with an average 12‑month price target of $241.85, a high around $289 and a low near $194 — about 6–7% upside from Friday’s close. ^[30]
Investing.com shows a very similar picture based on 29 analysts: average target roughly $243.55, high $289, low $184, and an overall “Buy” rating. ^[31]
Zacks data put the consensus target closer to $244.5 on 26 short‑term price targets, in line with the other sources. ^[32]

In other words, Wall Street’s base case is that AbbVie stock offers modest, not explosive, upside from current levels — but with a strong dividend and relatively defensive business model.

Fundamental metrics: P/E and payout ratio look “weird” for a reason

Some screens flag AbbVie’s valuation as expensive or distorted, for two reasons:

P/E ratio:
- Macrotrends reports a trailing P/E around 24x as of late November 2025. ^[33]
- Other data providers, using different earnings definitions that fully expense large R&D charges, show much higher P/E readings. ^[34]
Dividend payout ratio:
- MarketBeat‑derived articles cite a payout ratio north of 500%, which obviously looks unsustainable at face value. ^[35]

Both distortions trace back to one‑time, non‑cash heavy items:

On October 3, 2025, AbbVie disclosed it would take about $2.7 billion of in‑process R&D (IPR&D) charges in Q3 and trimmed its full‑year profit forecast at that time. ^[36]
Then, after reporting Q3 results on October 31, it raised 2025 guidance again as core operations out‑performed expectations, but the non‑recurring charges still weigh on GAAP earnings. ^[37]

The upshot:

Cash flow and adjusted earnings remain strong, which is why the board felt comfortable raising the dividend by 5.5% to $1.73 per quarter ($6.92 annualized). ^[38]
Headline P/E and payout ratios look scary mainly because accounting hits depressed GAAP EPS, not because the underlying business suddenly turned negative.

Fundamentals in Focus: Q3 2025 Results and 2025 Outlook

Even though Q3 numbers were released a month ago, they are repeatedly referenced in today’s news coverage and are crucial for interpreting AbbVie’s valuation.

Third‑quarter 2025 at a glance

According to AbbVie’s official releases and independent summaries: ^[39]

Net revenue: $15.78 billion, up 9.1% year‑over‑year, and ahead of consensus (~$15.59B).
GAAP diluted EPS:$0.10, down sharply due to IPR&D charges.
Adjusted diluted EPS:$1.86, beating analysts’ $1.77 expectation, though down vs. the prior year.

Product performance was highly skewed:

Skyrizi: ~$4.71 billion in Q3 sales, up ~47% YoY and above consensus.
Rinvoq: ~$2.18 billion, up ~35% YoY, also ahead of expectations.
Humira: $993 million, down 55% YoY and below the ~$1.15B consensus, marking the first quarter Humira has slipped below $1 billion in global sales.
Aesthetics (incl. Botox Cosmetic): fell about 3.7% vs. last year, which weighed on the stock reaction on earnings day. ^[40]

Guidance: Raised despite pricing headwinds

On that same October 31 call, AbbVie:

Raised 2025 adjusted EPS guidance to $10.61–$10.65, up from a prior range of $10.38–$10.58. ^[41]
Guided for roughly $16.3 billion in Q4 net sales, driven by ongoing Skyrizi and Rinvoq growth. ^[42]

However, management also flagged two key headwinds:

U.S. Medicare drug‑price negotiations
- AbbVie said the Trump administration is pushing for steeper price cuts in ongoing Medicare negotiations vs previous years, affecting drugs like Linzess and Vraylar—though the company doesn’t expect this to alter its long‑term guidance. ^[43]
Softness in aesthetics
- Sales of Botox and fillers disappointed as macroeconomic pressure and inflation weighed on discretionary spending. Analysts warned that further weakness could remain a concern if the slowdown persists. ^[44]

These issues show why today’s valuation articles stress both the strengths and risks in AbbVie’s story.

Other Recent Pipeline and Regulatory Updates to Know

While not all of these hit specifically on November 29, they’re frequently referenced in today’s analysis of AbbVie’s long‑term outlook:

LUPRON DEPOT (leuprolide acetate)
- On November 17, 2025, AbbVie announced that a new 6‑month 45 mg LUPRON DEPOT strength received Health Canada approval for treating advanced prostate cancer, adding another long‑acting oncology option to its portfolio. ^[45]
EPKINLY (epcoritamab‑bysp) + R2 in follicular lymphoma
- In mid‑November, AbbVie won U.S. FDA approval for EPKINLY in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma after at least one prior systemic therapy. Phase 3 data showed a 79% reduction in risk of progression or death versus standard R2, with high response rates and manageable safety. ^[46]
Rinvoq (upadacitinib) in vitiligo
- Late October topline Phase 3 results indicated Rinvoq achieved meaningful total‑body and facial repigmentation endpoints in non‑segmental vitiligo, potentially opening another autoimmune indication if regulators eventually approve it. ^[47]

Collectively, these developments support the view — echoed in today’s Simply Wall St and MarketBeat coverage — that AbbVie is methodically stacking new indications and geographies to keep Skyrizi, Rinvoq and newer oncology agents growing well past Humira’s decline. ^[48]

What Today’s News Means for AbbVie Stock

Pulling it together, here’s how the November 29, 2025 news cluster shapes the AbbVie (ABBV) investment narrative:

Pipeline momentum remains a clear positive.
- Skyrizi’s UC reimbursement in Canada reinforces its status as a global IBD cornerstone.
- New approvals and trial wins for EPKINLY, Rinvoq, LUPRON and Allergan Aesthetics products broaden AbbVie’s growth base beyond its traditional mainstays. ^[49]
Institutional investors are fine‑tuning, not fleeing.
- Today’s 13F headlines show high‑profile funds both trimming and adding to AbbVie, with overall institutional ownership still above 70%. ^[50]
- That’s consistent with a large, mature blue chip where professional investors constantly rebalance but generally maintain significant exposure.
Valuation is no longer a one‑way “bargain” story.
- Consensus price targets sit only mid‑single digits above the current share price. ^[51]
- Some models (DCF‑heavy) argue AbbVie is still deeply undervalued, while more conservative scenario‑based narratives see only modest upside. ^[52]
Key risks are well‑known but now front‑and‑center in the narrative.
- Medicare price cuts, global drug‑pricing reforms and aesthetic‑segment softness are the main issues analysts highlight in recent Reuters and earnings‑call coverage. ^[53]
- Accounting noise from large IPR&D charges makes some headline metrics (P/E, payout ratio) look alarming, but cash‑flow‑based measures paint a more stable picture. ^[54]

Bottom Line

As of November 29, 2025, AbbVie stock sits in an interesting spot:

Price: near all‑time highs after a ~30%+ run in 2025. ^[55]
Story: powerful immunology growth (Skyrizi, Rinvoq), new oncology approvals, and a still‑healthy aesthetics and neuroscience franchise. ^[56]
Sentiment: mostly constructive but no longer complacent, with analysts and institutions actively debating how much future growth is already in the share price. ^[57]

For investors tracking AbbVie stock news today, the takeaway is that fundamentals continue to improve, but valuation is catching up, making execution on Skyrizi, Rinvoq and the broader pipeline — as well as navigation of drug‑pricing reforms — the critical drivers of where ABBV trades next.

Disclaimer: This article is for informational and educational purposes only and is not financial advice or a recommendation to buy or sell any security. Always do your own research or consult a licensed financial adviser before making investment decisions.

Using the SKYRIZI On-Body Injector | See Abbv.ie/SkyriziPI